ProBio

🏆 ProBio Successfully Completes NMPA Pre-Approval Inspection for Biologics Manufacturing Facility in Nanjing, China ✅ A significant milestone in ProBio's biologics manufacturing journey! What does it take to support a biologics program from early development through critical regulatory milestones? Our latest achievement in Nanjing tells a story that goes beyond a successful inspection. In this issue of ProBio Pulse, we take you behind the milestone to explore the people, partnerships, and commitment that made it possible. 📖 Read the latest ProBio Pulse newsletter to discover the full story! 👉 Follow us: https://hubs.ly/Q04BrRFj0 #ProBioPulse #Biologics #GMPManufacturing #CDMO #Biopharma #newsletter #NMPA

🚀 New Webinar | Speed Without Compromise: From Complex Antibodies to Targeted Delivery Discover how innovative CMC strategies are accelerating the development of complex biologics, antibody fragments, and next-generation targeted delivery technologies. Join Liang (Leon) Tian and Ying Li for real-world case studies, expert insights, and practical approaches to bringing advanced therapeutics to the clinic faster. 📅 October 29, 2026 🕙 10:00-11:00 AM ET ✅ Can't attend live? Register anyway to receive complimentary on-demand access. 🔗 Register here: https://lnkd.in/gn_wMzpB #Biologics #CMC #BispecificAntibodies #AntibodyFragments #TargetedDelivery #CDMO #Webinar

Innovation isn't the only challenge in cell and gene therapy. Scaling innovation is. Evolving regulations, complex tech transfer, and manufacturing variability can add time, cost, and risk to CGT programs. Discover practical strategies to strengthen regulatory readiness, de-risk tech transfer, and build scalable manufacturing. Download the CGT Handbook to explore a more predictable path to market.

AI has largely solved the candidate generation problem. 𝐓𝐡𝐞 𝐧𝐞𝐰 𝐛𝐨𝐭𝐭𝐥𝐞𝐧𝐞𝐜𝐤? 𝐕𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧. As AI platforms generate thousands of antibody candidates, the challenge is no longer finding molecules that bind. It's identifying the few that are functional, developable, and capable of becoming medicines. The competitive advantage in AI-driven drug discovery will increasingly belong to organizations that can validate, prioritize, and advance the right candidates faster. At ProBio, we're helping bridge the gap between AI prediction and therapeutic reality through integrated AIDD, validation, developability, and CMC capabilities. AI creates possibilities. Validation identifies the winners. 📍Heading to CPHI Milan? Visit the ProBio team at Hall 8, Booth D76 from 6-8 October to discuss how we're helping innovators bridge the gap between AI design and real-world drug development.

In vivo CAR-T is changing how advanced therapies are developed, but innovation is only part of the story. Our latest article in Nordic Life Sciences explores in vivo cell therapy, investigator-initiated trials, and the growing role of global evidence generation and what these developments could mean for the next phase of advanced therapies. At ProBio, we support advanced therapy developers in connecting scientific innovation with practical execution, from plasmid DNA and viral vectors to mRNA, cell and gene therapy development, IIT support, and GMP manufacturing. Read the full article to explore how the right development strategy can help bring these innovations closer to patients.

Next‑Gen Strategies in Early Antibody Discovery | June 3 Functional screening remains a key bottleneck in antibody discovery. Join ProBio’s live webinar to learn how early functional validation can shorten development timelines, improve hit rates, and accelerate progress from concept to candidate. 🎯 What you’ll gain: • How to enable earlier functional screening • Platform insights across Hybridoma, Single B Cell, and Phage Display • Real case studies showing faster turnaround and higher efficiency Speaker: Dr. Derek Chen, Senior Director, Antibody Drug Discovery This webinar will be delivered twice to accommodate global audiences. 👉 Register now to secure your spot. 🕘 EMEA: https://lnkd.in/eztTjJm2 🕘 Americas: https://lnkd.in/e_PWir27